Amryt reports higher revenue in Q2, increases guidance
Dublin-based biopharmaceutical group Amryt, which specialises in the development of treatments for rare diseases, has reported revenue of $62.8m for the second quarter of the year - up 35.9% on the same period last year.
Business
• 06 Aug 21
